Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Canatu H1'26: Growth story takes more hits, long game still alive

CANATUResearch2026-08-26 11:15
Atte RiikolaAnalyst
Discuss
Download report (PDF)

Summary

  • The analyst reiterates an Accumulate recommendation for Canatu but lowers the target price to EUR 7.0 due to decreased estimates, citing weak H1 figures and a disappointing outlook for 2026.
  • Canatu's H1 revenue fell by 43% to 4.2 MEUR, significantly below forecasts, primarily due to a collapse in the semiconductor sector, impacting sales of inspection membranes.
  • The company's revenue for 2026 is expected to decline significantly from 2025 levels, with the semiconductor sector's reactor business being crucial for future growth, although visibility into new commercial breakthroughs remains weak.
  • Despite recent setbacks, Canatu's long-term growth potential remains credible, supported by a new reactor order from FST, indicating progress in the reactor business and potential for strong earnings growth in the coming years.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 8/26/2026 at 7:00 am EEST.

We reiterate our Accumulate recommendation, but lower our target price to EUR 7.0 (was EUR 8.5) on the back of decreased estimates. Canatu's long-term growth story remains attractive, and the new reactor order from FST confirms our view that Canatu's technology is in a strong position in the emerging CNT pellicle market. However, the H1 figures were very weak compared to expectations, and the weak outlook for the full year 2026 practically means kicking the growth can down the road for the second year in a row. Investor disappointment is reflected in the fallen share price, and in our view, Canatu's current enterprise value (2026e 144 MEUR) is low relative to the company's potential if the updated strategy succeeds. Therefore, we still see the risk/reward ratio as sufficient, but a sustained share price increase will likely require concrete evidence of scalable growth in the coming years. 

Very weak H1 figures

In line with the preliminary information provided on Monday, Canatu’s H1 revenue decreased by 43% to 4.2 MEUR, driven particularly by the collapse of the semiconductor sector (0.4 MEUR vs. 5.7 MEUR). This was clearly below our forecast of 8.5 MEUR, which is particularly reflected in the sharp decline in sales of inspection membranes as a major customer digests its inventories (the products have proven more durable than expected). Canatu’s H1 EBITDA decreased significantly year-on-year and was -11.4 MEUR. This was clearly below our forecast of -6.9 MEUR and is largely explained by revenue falling short of expectations.

Estimates for coming years decreased significantly

In connection with the new reactor order announced on Monday, Canatu already provided an updated outlook for 2026. According to the company, revenue in 2026 will decline significantly from the 2025 level (15.6 MEUR). This was a clear disappointment compared to our expectations, as we had previously forecast a revenue of 21.8 MEUR for the current year (now 9.6 MEUR). In the next few years, the key aspect for Canatu's growth will be the progress of the semiconductor sector's reactor business. According to the company, negotiations with new reactor customers have progressed, but at this stage, external visibility into new commercial breakthroughs is weak. In our view, the order for a second reactor received from FST on Monday confirms that Canatu's technology works and that FST is preparing for growing volume deliveries to its end customers in the coming years. The next steps toward mass production are the product approvals of FST's end customers (based on public sources, e.g., Samsung) in pilot and risk production. Therefore, the timeline on which Canatu will start generating recurring revenue from these two reactors is beyond the company's control. The customer acceptance process for the second reactor customer is still ongoing. The company was relatively tight-lipped about the situation, but it would seem that the delay is more dependent on the customer than on Canatu.

Long-term potential still alive

The declining revenue and missing growth targets in 2025–2026 have taken a clear toll on Canatu's growth story, which has been strongly reflected in the declining share price and forecasts. Despite the decline in the share price, Canatu's valuation (2026e EV/S 15x) has priced in expectations of strong scalable growth, for which we believe the still credible long-term growth story provides grounds. The company's reactor business is progressing in the right direction, of which FST's new reactor order is a concrete and important indication.  This creates a foundation for gradually accelerating and strong earnings growth in the coming years. Should this materialize, the share’s valuation (2030e EV/S ~2x and EV/EBIT ~8x) will become attractive, and the growth outlook would presumably remain strong even after that. Through scenarios modeling growth and profitability at different rates, we have estimated a wide value range of some EUR 3-14 for Canatu, which partly reflects the risks and opportunities associated with the company.

Canatu is a technology company active in deep technology that creates carbon nanotubes (Canatu CNT), related products and manufacturing equipment for the semiconductor, automotive and medical diagnostics industries. The company operates through two business models, firstly using their own reactors to develop and manufacture CNT products. Second, the company sells its CNT reactors and licenses its related technology, allowing customers to produce the products themselves under a limited license.

Read more on company page

Key Estimate Figures25/08

202526e27e
Revenue15.69.625.6
growth-%-29.2 %-38.6 %167.5 %
EBIT (adj.)-10.2-22.7-12.4
EBIT-% (adj.)-65.1 %-236.6 %-48.5 %
EPS (adj.)-0.27-0.56-0.27
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Insider buying Ann-Sofi Reims 255 shares in addition to the previous 639 shares Salminen Tapani 560 shares. Apparently no previous holdings.
yesterday
by TurskaSaavi
5
Here is a new company report on Canatu from Inderes following the latest news. We reiterate our Accumulate rating for Canatu, but lower our ...
8/26/2026, 4:58 AM
by Sijoittaja-alokas
12
Yes, those FST pellicles are definitely going to Samsung. Here is some news where equipment is being ordered for Taylor, which could point to...
8/25/2026, 7:03 PM
8
Have you analyzed this yet: Korean Tech Texas – 27 Apr 26 FST's Hutto Plant: The Korean Pellicle Maker Quietly Holding Samsung's 2nm... Samsung...
8/25/2026, 6:16 PM
by StockTycoon
4
Today’s news dug up from Korea. Translated via browser. Aju News. Semiconductor pellicle manufacturer FST is acquiring additional carbon nanotube...
8/25/2026, 3:55 PM
by TurskaSaavi
17
CEO Slawinski in Atte Riikola’s interview: Canatu H1’26: Sharper Focus with a New Strategy
8/25/2026, 2:28 PM
8
Samsung has a stake in FST. It is no secret that Samsung wants to use pellicles at its Taylor factory.
8/25/2026, 1:22 PM
by pellicle
0